Abstract
Pneumococcal infections are still a major health problem worldwide. They can affect a person in any age, the most common and most dangerous, however, are in young children and the elderly.
The listed risk groups are endangered by the difficult course immunocompromised patients. Severe pneumococcal disease, referred to as invasive pneumococcal infection (IPO), when pneumococcus gets into the bloodstream, they include sepsis, pneumonia, meningitis, rarely septic arthritis, endocarditis and peritonitis.
More common but less serious forms of the disease are infections of the upper and lower respiratory tract, ie. otitis media (AMO), sinusitis, pharyngitis, bronchitis, or pneumonia. It is a bacterial infection that we treat causally with antibiotics.
In recent years, Resistance of pneumococci to commonly used antibiotics is significantly increasing. The cause is the overuse of antibiotics for respiratory infections tech.
It is known that mainly macrolides, cotrimoxazole, but also cephalosporins select resistant pneumococci faster than aminopenicillins. Therefore, amoxicillin is the drug of choice in IHCD; in IPO, G-penicillin remains the drug of choice in high doses, possibly. cephalosporins II. and III. generation (2).
Today, pneumococcal infection is one of the preventable diseases, ie we can prevent the disease by applying a vaccine, or at least mitigate its course. Selected case reports draw attention to the severity of the disease with an unfavorable course even when given on time comprehensive treatment and therefore prevention should not be underestimated.